Browsing by Author Gil Gil, Miguel

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)
14-Apr-2023CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2−Metastatic Breast CancerGuerrero Zotano, Ángel; Belli, Stefania; Zielinski, Christoph; Gil Gil, Miguel; Fernández Serra, Antonio; Ruíz Borrego, Manuel; Ciruelos Gil, Eva María; Pascual, Javier; Muñoz Mateu, Montserrat; Bermejo, Begoña; Margeli Vila, Mireia; Antón, Antonio; Murillo, Laura; Nissenbaum, Bella; Liu, Yuan; Herranz, Jesús; Fernández García, Daniel; Caballero, Rosalía; López Guerrero, José Antonio; Bianco, Roberto; Formisano, Luigi; Turner, Nicholas; Martín, Miguel
25-Sep-2019PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single InstitutionPernas, Sònia; Petit, Anna; Climent, Fina; Paré, Laia; Perez Martin, J.; Ventura, Luz; Bergamino Sirvén, Milana; Galván, Patricia; Falo, Catalina; Morilla, Idoia; Fernandez Ortega, Adela; Stradella, Stradella; Rey, Montse; Garcia Tejedor, Amparo; Gil Gil, Miguel; Prat Aparicio, Aleix
6-Sep-2012Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a restrospective cohort study in Catalonia, Spain.Font, Rebeca; Espinàs Piñol, Josep Alfons; Gil Gil, Miguel; Barnadas i Molins, Agustí; Ojeda, B.; Tusquets, Ignasi; Seguí, Miquel A.; Margelí Vila, Mireia; Arcusa, Angels; Prat Marín, Andrés; García, M.; Borràs Andrés, Josep Maria
31-Jul-2019Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patientsEstival, Anna; Sanz, Carolina; Ramirez, Jose Luis; Velarde, Jose Maria; Domenech, Marta; Carrato, Cristina; Peñas, Ramón de las; Gil Gil, Miguel; Sepúlveda, Juan; Armengol, Roser; Cardiel, Isaac; Berrocal, Alfonso; Luque, Raquel; Herrero, Ana; Balana, Carmen
21-Nov-2019Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer centerSirven, Milana Bergamino; Fernández Ortega, Adela; Stradella, Agostina; Morilla, Idoia; Falo, Catalina; Vázquez, Silvia; Castany, Roser; Villanueva, Rafael; Recalde, Sabela; Navarro Pérez, Valentí; Gil Gil, Miguel; Pernas, Sònia
12-Feb-2020Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancerÁlvarez López, Isabel; Bezares, S.; Dalmau Portulas, E.; García Martínez, E.; García Sáenz, José Ángel; Gil Gil, Miguel; Martínez de Dueñas, E.; Ribelles, N.; Santaballa Bertrán, A.
12-May-2022Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 TrialMartínez García, María; Velasco, Guillermo; Pineda, Estela; Gil Gil, Miguel; Alameda, Francesc; Capellades, Jaume; Martín Soberón, Mari Cruz; López Valero, Israel; Tovar Ambel, Elena; Foro, Palmira; Taus, Álvaro; Arumi, Montserrat; Hernández Laín, Aurelio; Sepúlveda Sánchez, Juan Manuel
1-Jul-2021The role of CDK4/6 inhibitors in early breast cancerGil Gil, Miguel; Alba, Emilio; Gavilá, Joaquín; Haba Rodríguez, Juan de la; Ciruelos, Eva; Tolosa, Pablo; Candini, Daniele; Llombart Cussac, Antonio
7-Jul-2022Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerModi, Shaun; Jacot, William; Yamashita, Toshinari; Sohn, Joohyuk; Vidal, Maria; Tokunaga, Eriko; Tsurutani, Junji; Ueno,Naoto T.; Prat Aparicio, Aleix; Chae, Yee Soo; Lee, Keun Seok; Niikura, Naoki; Park, Yeon Hee; Xu, Binghe; Wang, Xiaojia; Gil Gil, Miguel; Li, Wei; Pierga, Jean Yves; Im, Seock-Ah; Moore, Halle C.F.; Rugo, Hope S.; Yerushalmi, Rinat; Zagouri, Flora; Gombos, Andrea; Ki, Sung Bae; Liu, Qiang; Luo, Ting; Saura, Cristina; Schmid, Peter; Sun,Tao; Gambhire, Dhiraj; Yung, Lotus; Wang, Yibin; Singh, Jasmeet; Vitazka, Patrik; Meinhardt, Gerold; Harbeck, Nadia; Camero, David A.